资金流向方面，主力资金净流出1964.05万元，特大单买入0.00元，占比0.00%，卖出1785.97万元，占比 14.56%；大单买入2001.59万元，占比16.32%，卖出2179.67万元，占比17.77%。 天康生物今年以来股价涨12.32%，近5个交易日跌3.79%，近20日跌5.83%，近60日涨7.24%。 资料显示，天康生物股份有限公司位于新疆维吾尔自治区乌鲁木齐市高新区长春南路528号天康企业大 厦，成立日期2000年12月28日，上市日期2006年12月26日，公司主营业务涉及畜禽用生物疫苗、饲料及 饲用植物蛋白的生产、销售,种猪繁育、生猪养殖、屠宰加工及肉制品销售。主营业务收入构成为：生 猪养殖产业链收入32.20%，饲料收入27.51%，蛋白油脂加工收入16.37%，玉米收入14.75%，兽药收入 5.44%，其他收入3.40%，其他(补充)0.29%，担保费收入0.04%。 天康生物所属申万行业为：农林牧渔-饲料-畜禽饲料。所属概念板块包括：疫苗、宠物经济、动物疫 苗、猪肉概念、融资融券等。 12月1日，天康生物盘中下跌2.07%，截至13:29，报7.11元/股，成交1.23亿 ...

Core Viewpoint - TianKang Biological has shown a mixed performance in stock price and financial results, with a notable increase in stock price year-to-date but a decline in net profit for the recent period [1][2]. Group 1: Stock Performance - On November 7, TianKang Biological's stock rose by 2.03%, reaching 7.53 CNY per share, with a trading volume of 80.02 million CNY and a turnover rate of 0.79% [1]. - The stock has increased by 18.96% year-to-date, with a 2.03% rise in the last five trading days, a 2.46% decline over the last 20 days, and a 16.74% increase over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, TianKang Biological reported a revenue of 13.61 billion CNY, representing a year-on-year growth of 4.00%, while the net profit attributable to shareholders decreased by 27.20% to 412 million CNY [2]. - The company has distributed a total of 1.89 billion CNY in dividends since its A-share listing, with 598 million CNY distributed in the last three years [3]. Group 3: Business Overview - TianKang Biological, established on December 28, 2000, and listed on December 26, 2006, is based in Urumqi, Xinjiang, and specializes in the production and sales of biological vaccines for livestock, feed, and plant protein [1]. - The revenue composition of the company includes 32.20% from the pig breeding industry chain, 27.51% from feed, 16.37% from protein and oil processing, 14.75% from corn, 5.44% from veterinary drugs, and 3.40% from other sources [1]. Group 4: Shareholder Information - As of October 31, the number of shareholders for TianKang Biological was 58,000, a decrease of 3.11% from the previous period, with an average of 23,548 circulating shares per shareholder, an increase of 3.21% [2]. - Notable institutional holdings include Guotai Zhongzheng Livestock Breeding ETF as the fifth-largest shareholder with 24.30 million shares, and Hong Kong Central Clearing Limited as the seventh-largest shareholder with 15.03 million shares, marking a new entry [3].

Core Viewpoint - TianKang Biological experienced a stock price increase of 2.03% on November 3, reaching 7.53 CNY per share, with a total market capitalization of 10.28 billion CNY [1] Company Overview - TianKang Biological Co., Ltd. is located in Urumqi, Xinjiang, and was established on December 28, 2000, with its stock listed on December 26, 2006 [1] - The company specializes in the production and sales of biological vaccines for livestock and poultry, feed, plant protein, breeding of breeding pigs, pig farming, slaughter processing, and meat product sales [1] - The revenue composition includes: 32.20% from pig farming, 27.51% from feed, 16.37% from protein and oil processing, 14.75% from corn, 5.44% from veterinary drugs, and 3.40% from other sources [1] Financial Performance - For the period from January to September 2025, TianKang Biological achieved an operating income of 13.61 billion CNY, representing a year-on-year growth of 4.00%, while the net profit attributable to shareholders decreased by 27.20% to 412 million CNY [2] - The company has distributed a total of 1.89 billion CNY in dividends since its A-share listing, with 598 million CNY distributed over the past three years [3] Shareholder Information - As of October 20, 2025, the number of shareholders decreased by 1.20% to 59,800, while the average number of circulating shares per person increased by 1.21% to 22,815 shares [2] - Notable institutional holdings include: Guotai Zhongzheng Livestock Breeding ETF as the fifth largest shareholder with 24.30 million shares, an increase of 8.75 million shares; Hong Kong Central Clearing Limited as the seventh largest shareholder with 15.03 million shares, a new entry; and Jiashi Agricultural Industry Stock A as the eighth largest shareholder with 13.91 million shares, an increase of 3.61 million shares [3]

Core Viewpoint - TianKang Biological is a leading domestic supplier of biological vaccines and feed for livestock and poultry, with significant investment value due to its full industry chain advantages [1] Group 1: Business Performance - In Q3 2025, TianKang Biological achieved operating revenue of 13.61 billion, ranking 4th among 10 companies in the industry, with the top company, HeFeng Co., at 28.07 billion [2] - The net profit for the same period was 505 million, ranking 1st in the industry, with the second being AoNong Biological at 439 million [2] - The revenue composition includes 2.85 billion from the pig breeding industry chain, accounting for 32.20%, and 2.43 billion from feed, accounting for 27.51% [2] Group 2: Financial Ratios - As of Q3 2025, the asset-liability ratio was 47.86%, lower than the previous year's 49.89% and below the industry average of 54.11% [3] - The gross profit margin was 10.88%, down from 11.99% year-on-year but still above the industry average of 9.94% [3] Group 3: Management and Shareholder Structure - The total compensation for General Manager Cheng Hui was 829,500, an increase of 229,500 from the previous year [4] - The largest shareholder is the Xinjiang Production and Construction Corps State-owned Assets Management Co., Ltd. [4] Group 4: Shareholder Changes - As of September 30, 2025, the number of A-share shareholders decreased by 3.42% to 60,600 [5] - The average number of circulating A-shares held per household increased by 3.54% to 22,500 [5] Group 5: Future Outlook - According to Citic Securities, revenue is expected to grow by 4.00% year-on-year, while net profit is projected to decline by 27.20% [6] - The company is expected to achieve revenues of 16.79 billion, 17.47 billion, and 18.02 billion from 2025 to 2027, with net profits of 446 million, 723 million, and 928 million respectively [6] - Pacific Securities anticipates a net profit of 777 million and 1.315 billion for 2025 and 2026, respectively [6]

Core Viewpoint - TianKang Biological experienced a stock price decline of 2.05% on October 22, 2023, with a current price of 7.65 CNY per share and a total market capitalization of 10.44 billion CNY [1] Company Overview - TianKang Biological Co., Ltd. was established on December 28, 2000, and listed on December 26, 2006. The company is located in Urumqi, Xinjiang, and its main business includes the production and sale of biological vaccines for livestock and poultry, feed, and plant protein, as well as pig breeding, pig farming, slaughtering, and meat product sales [1] - The revenue composition of TianKang Biological includes: 32.20% from the pig farming industry chain, 27.51% from feed, 16.37% from protein and oil processing, 14.75% from corn, 5.44% from veterinary drugs, 3.40% from other income, 0.29% from supplementary income, and 0.04% from guarantee fees [1] Financial Performance - For the first half of 2025, TianKang Biological achieved an operating income of 8.847 billion CNY, representing a year-on-year growth of 10.68%. The net profit attributable to the parent company was 338 million CNY, with a year-on-year increase of 22.27% [2] - Since its A-share listing, TianKang Biological has distributed a total of 1.891 billion CNY in dividends, with 598 million CNY distributed in the last three years [3] Shareholder Information - As of September 30, 2023, TianKang Biological had 60,600 shareholders, a decrease of 3.42% from the previous period. The average circulating shares per person increased by 3.54% to 22,542 shares [2] - The top ten circulating shareholders include notable institutional investors such as Guotai Junan Zhongzheng Livestock Breeding ETF and Harvest Agricultural Industry Stock A, with significant increases in their holdings [3]

Core Viewpoint - TianKang Biological has shown a positive stock performance with a year-to-date increase of 23.70% and a market capitalization of 10.69 billion yuan as of October 17 [1] Company Overview - TianKang Biological Co., Ltd. is located in Urumqi, Xinjiang, and was established on December 28, 2000, with its stock listed on December 26, 2006 [1] - The company specializes in the production and sales of biological vaccines for livestock and poultry, feed, and plant protein, as well as pig breeding, pig farming, slaughter processing, and meat product sales [1] Financial Performance - For the first half of 2025, TianKang Biological achieved an operating income of 8.847 billion yuan, representing a year-on-year growth of 10.68%, and a net profit attributable to shareholders of 338 million yuan, up 22.27% year-on-year [2] - Cumulatively, the company has distributed 1.891 billion yuan in dividends since its A-share listing, with 598 million yuan distributed over the past three years [3] Shareholder Information - As of September 30, the number of shareholders for TianKang Biological was 60,600, a decrease of 3.42% from the previous period, with an average of 22,542 circulating shares per shareholder, an increase of 3.54% [2] - The top ten circulating shareholders include notable funds such as Guotai Zhongzheng Livestock Breeding ETF and Jiashi Agricultural Industry Stock A, with increases in their holdings [3]

Core Points - TianKang Bio's stock price has increased by 15.48% year-to-date, but has seen a decline of 2.66% in the last five trading days [2] - The company reported a revenue of 8.847 billion yuan for the first half of 2025, representing a year-on-year growth of 10.68%, with a net profit of 338 million yuan, up 22.27% [2] - The company has distributed a total of 1.891 billion yuan in dividends since its A-share listing, with 598 million yuan distributed in the last three years [3] Company Overview - TianKang Bio, established on December 28, 2000, and listed on December 26, 2006, is located in Urumqi, Xinjiang, and specializes in the production and sales of biological vaccines for livestock, feed, and plant protein [2] - The revenue composition of TianKang Bio includes 32.20% from the pig breeding industry chain, 27.51% from feed, 16.37% from protein and oil processing, 14.75% from corn, 5.44% from veterinary drugs, and 3.40% from other sources [2] - As of September 19, 2025, the number of shareholders is 62,700, a decrease of 9.64% from the previous period, with an average of 21,770 circulating shares per person, an increase of 10.67% [2] Institutional Holdings - As of June 30, 2025, the sixth largest circulating shareholder is Guotai Zhongzheng Livestock Breeding ETF, holding 15.5491 million shares, an increase of 641,000 shares from the previous period [3] - The ninth largest circulating shareholder is Harvest Agricultural Industry Stock A, holding 10.2945 million shares, an increase of 630,100 shares [3] - The tenth largest circulating shareholder is Southern Zhongzheng 1000 ETF, holding 10.0839 million shares, an increase of 1.8978 million shares [3]

Core Viewpoint - TianKang Biological has shown a significant increase in stock price and trading volume, indicating positive market sentiment and potential growth in the agricultural and livestock sector [1][2]. Company Overview - TianKang Biological Co., Ltd. is located in Urumqi, Xinjiang, and was established on December 28, 2000, with its stock listed on December 26, 2006. The company specializes in the production and sales of biological vaccines for livestock, feed, and plant protein, as well as pig breeding, pig farming, slaughter processing, and meat product sales [1]. - The revenue composition of TianKang Biological includes: 32.20% from pig farming, 27.51% from feed, 16.37% from protein and oil processing, 14.75% from corn, 5.44% from veterinary drugs, and 3.40% from other sources [1]. Financial Performance - For the first half of 2025, TianKang Biological achieved an operating income of 8.847 billion yuan, representing a year-on-year growth of 10.68%. The net profit attributable to the parent company was 338 million yuan, reflecting a year-on-year increase of 22.27% [2]. - Since its A-share listing, TianKang Biological has distributed a total of 1.891 billion yuan in dividends, with 598 million yuan distributed over the past three years [3]. Shareholder Information - As of September 10, 2025, the number of shareholders of TianKang Biological was 69,400, an increase of 1.60% from the previous period. The average number of circulating shares per person decreased by 1.57% to 19,672 shares [2]. - Notable institutional shareholders include Guotai Zhongzheng Livestock Breeding ETF, which holds 15.5491 million shares, and Jiashi Agricultural Industry Stock A, holding 10.2945 million shares, both of which have increased their holdings compared to the previous period [3].